Background {#Sec1}
==========

Stress-induced analgesia (SIA) is an evolutionarily protective system in mammals for coping with environmental stressors \[[@CR1]\]. Several neuropeptides released during stress, such as orexins \[[@CR2], [@CR3]\], neuropeptide S (NPS) \[[@CR4]\] and substance P \[[@CR5]\], may contribute to SIA. However, how these neuropeptide-mediated signals interact to elicit SIA remains unknown.

Orexins, consisting of orexin-A and orexin-B \[[@CR6]\], also known as hypocretin-1 and hypocretin-2 \[[@CR7]\], are processed from preprohypocretin in hypothalamic neurons in the perifornical area (PFA), lateral hypothalamus (LH) and dorsomedial hypothalamus (DMH) \[[@CR6], [@CR7]\]. Orexin receptors, OX~1~ receptors (OX~1~Rs) and OX~2~ receptors (OX~2~Rs), belong to the G-protein coupled receptor (GPCR) family \[[@CR8]\]. In addition to being involved in arousal and reward regulation \[[@CR9]\], orexins are antinociceptive \[[@CR10]--[@CR12]\] and are involved in SIA \[[@CR2], [@CR3], [@CR12], [@CR13]\]. Previously, we have shown that orexins can be released during stress and contribute to SIA, at least in part, via opioid-independent and endocannabinoid (eCB)-dependent signaling \[[@CR11], [@CR12]\] in the ventrolateral periaqueductal gray (vlPAG), a crucial midbrain region for the initiation of descending pain inhibition \[[@CR14], [@CR15]\]. Specifically, orexins are released during stress \[[@CR12]\], and orexins are known to induce antinociception by activating postsynaptic OX~1~Rs to generate 2-arachidonoylglycerol (2-AG) \[[@CR16], [@CR17]\], an eCB, through a Gq protein-coupled enzymatic cascade mediated by phospholipase C (PLC) and diacylglycerol lipase (DAGL) \[[@CR18]\], culminating in retrograde inhibition of GABA release (disinhibition) in the vlPAG \[[@CR11], [@CR12]\].

NPS is an icosapeptide named due to its conserved N-terminal residue, serine, in all species \[[@CR4]\]. Central administration of NPS (intra-cerebroventricular, *i.c.v.*) is antinociceptive \[[@CR19]--[@CR21]\]. The site of this antinociceptive action could be the PAG, where the mRNA transcript of NPS receptors (NPSRs) is abundant \[[@CR22], [@CR23]\], or other NPSR-rich brain regions, such as the amygdala and hypothalamus \[[@CR22]\]. All three areas are commonly associated with emotional behaviours, and NPS is therefore implicated in stress-related behaviours. Indeed, forced swimming or restraint stress significantly activated NPS neurons in the pericoerulear region (peri-LC) and the Kölliker-Fuse nucleus of the lateral parabrachial area (KF-PBN) \[[@CR24]\]. Intra-paraventricular nucleus (PVN) or *i.c.v.* administration of NPS in mice increased their locomotor and rearing activity, and plasma adrenocorticotropic hormone (ACTH) and corticosterone levels, suggesting that NPS can activate the arousal system and the hypothalamus-pituitary axis (HPA) \[[@CR25]\].

The findings that both NPS and orexins are involved in the regulation of arousal, reward and pain suggest an interaction between the NPS \[[@CR26]\] and orexin systems \[[@CR9]\]. Indeed, it has been demonstrated that NPS (*i.c.v.*) can activate orexin neurons in the LH, PFA and DMH of rats \[[@CR27], [@CR28]\], where NPSRs are abundantly expressed \[[@CR23]\]. Moreover, NPS has been reported to be an upstream activator of hypothalamic orexin neurons in feeding \[[@CR27]\] and addiction \[[@CR28], [@CR29]\] behaviours. This suggests that NPS can activate orexin neurons and exert its biological functions, possibly including SIA, indirectly, by promoting the release of orexins.

Substance P is an undecapeptide belonging to the neurokinin (tachykinin) family \[[@CR30]\] and exerts its effects mainly via NK~1~ receptors (NK~1~Rs) \[[@CR31]\], a member of the GPCR family. Substance P is a well-known peripheral pronociceptive mediator \[[@CR32]\] while it is antinociceptive at the supraspinal level \[[@CR33]\]. In fact, intra-PAG microinjection (*i.pag.*) of substance P induces antinociception \[[@CR34]\]. This effect may be mediated by the NK~1~Rs in the PAG since it is blocked by an NK~1~R antagonist and NK~1~Rs are densely distributed in pain-modulating brain regions including the PAG \[[@CR35]\].

Using an electrophysiological approach, Drew et al. (2009) \[[@CR36]\] have investigated how substance P modulates synaptic transmission in brain slices containing the vlPAG. They demonstrated that substance P decreased evoked GABA release in vlPAG slices. This effect was abolished by an inhibitor of DAGL, a degradation enzyme of 2-AG, and an antagonist of mGlu~5~ receptors (mGlu~5~R). Importantly, a glutamate transporter inhibitor mimicked the GABA-reducing effect of substance P, but also occluded such action of substance P \[[@CR37]\]. However, substance P markedly increased action potential-driven spontaneous glutamate release. It is suggested that substance P induces an enormous release of glutamate that may activate perisynaptic mGlu~5~R to initiate the eCB-mediated retrograde disinhibition mechanism in the vlPAG. They suggested this effect may contribute to the substance P-induced analgesic effect in the vlPAG \[[@CR37]\], however no pain behaviors were not evaluated. Substance P in the PAG may also contribute to SIA since restraint stress \[[@CR38]\] and LH stimulation \[[@CR39]\] increased the substance P level in the PAG and *i.pag.* blockade of NK~1~Rs abolished LH-stimulation-induced antinociception. However, there are no direct in vivo studies supporting the involvement of PAG substance P in SIA. Taking into consideration the the complexity of the aforementioned neuropeptides in SIA, a scheme depicting the possible relationships among NPS, orexins, substance P, mGlu~5~R and eCB (2-AG) during SIA, based on the available literature, is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1A schema depicting the possible relationships among NPS, orexins, substance P, mGlu~5~R and endocannabinoid (2-AG) during SIA, based on the available literature. The cascades occurring in the locus coeruleus (LC)/ parabrachial nucleus (PBN), lateral hypothalamus (LH) and periaqueductal gray (PAG) during stress or exposing to NPS (purple), orexins (red) or substance P (blue) are depicted in the right box. The findings that have been reported are shown by solid lines with the numbers of referred literatures. To fulfil our hypothesis, the links that have to be proven are now established in this study, which are denoted by broken lines marked with \[★\]. The images of mouse brain and neurons are adapted from Illustration Toolkit Neuroscience by Motifolio. PN: projection neuron; SubP: substance P; Glu: glutamate

Substance P-induced vlPAG disinhibition, which is mediated through mGlu~5~R-initiated eCB signaling, highly resembles the OX~1~R-initiated 2-AG/CB~1~R signaling we reported previously \[[@CR11]\], which contributes to SIA \[[@CR12]\]. Moreover, mGlu~5~R \[[@CR40]\] and eCBs \[[@CR41], [@CR42]\] are also involved in SIA. These events, all taking place in the vlPAG, prompted us to hypothesize the involvement of NK~1~Rs and mGlu~5~Rs in orexin-induced antinociception, and subsequently their involvement in SIA, possibly as downstream effectors of NPS. In this study, via behavioral, pharmacological and neurochemical approaches, we first examined the involvement of NK~1~R, mGlu~5~Rs and CB~1~Rs in substance P-induced antinociception. Next, we investigated whether orexins are upstream to substance P in the vlPAG in eliciting antinociceptive effects. Then, we examined whether NPS is an upstream modulator of LH orexin neurons. Lastly, we studied the involvement of the NPSR-OX~1~R-NK~1~R-mGlu~5~R-CB~1~R pathway in SIA.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

All animal experiments were approved by the Institutional Animal Care and Use Committee of College of Medicine, National Taiwan University following ARRIVE guidelines. Male C57BL/6 mice of 8--12 weeks were housed in groups of 10 in plastic cages and maintained in a holding room with a 12 h light-dark cycle with free access to food and water ad libitum. On the experimental day, mice were moved in their home cages to the behaviour room and acclimated there for at least 1 h before testing.

Hot-plate test {#Sec4}
--------------

The hot-plate test in mice was performed as reported previously \[[@CR12]\]. Briefly, the mouse was placed on a hot-plate maintained at 50 °C and paw withdrawal latency was recorded with a cut-off time of 60 s to prevent tissue damage. The antinociceptive effect in each mouse at each time point was calculated as the % of the maximal possible effect (MPE) by the equation: %MPE = 100 x (Latency~after\ treatment~ - Latency~before\ treatment~) / (60s - Latency~before\ treatment~). The AUC of withdrawal latencies during the 60 min-recording period was calculated as the total antinociceptive effect in each mouse.

SIA {#Sec5}
---

To induce SIA, mice were restrained in a 50-ml centrifugal tube with several small holes for 30 min as reported previously \[[@CR12]\]. The control non-stress group of mice remained at their home cages for the same 30 min before being subjected to the hot-plate test.

Spontaneous locomotor activity {#Sec6}
------------------------------

Locomotor activity was assessed by an open-field test in a 48 × 48 × 40 cm^3^ acrylic chamber with the arena floor divided into 36 squares, as described previously \[[@CR43]\]. The mouse was placed in the center of the chamber, and the number of squares the mouse transpassed with forepaws (number of crossing) and the number of times the mouse stood up with forepaws on the floor (number of rearing) were counted for 5 min.

Intra-vlPAG (*i.pag.*) and intra-cerebroventricular (*i.c.v.*) microinjection {#Sec7}
-----------------------------------------------------------------------------

When drugs were given by *i.pag.* or *i.c.v.* microinjection, mice received the *i.pag.* or *i.c.v.* cannulation surgery 1 week before the microinjection experiment, as reported previously \[[@CR12]\]. Briefly, under anesthesia with 50 mg/kg Zoletil® 50 (a mixture of tiletamine and zolazepam) and xylazine (10 mg/kg), the mouse was placed in a stereotaxic apparatus and a 24-gauge, 10 mm stainless-steel guide cannula was implanted into the right vlPAG (− 4.8 mm caudal, − 0.5 mm lateral, − 2.8 mm ventral from bregma, Additional file [1](#MOESM1){ref-type="media"}: Figure S1A) or the right ventricle (− 0.5 mm caudal, − 1.0 mm lateral, − 2.2 mm ventral from bregma, Additional file [1](#MOESM1){ref-type="media"}: Figure S1B), according to stereotaxic coordinates of mice \[[@CR44]\]. On the day of experiments, *i.pag.* or *i.c.v.* microinjection was performed through a 30-gauge injection needle (10 mm) connected to a Hamilton syringe (1.0 μl) on a microinfusion pump (KDS311, KD Scientific Inc., Holliston, MA, USA). The drug solution (0.1 μl) was delivered in 60 s, followed by a 240 s-residual time to avoid back-flow of drug solution. Nociceptive responses were measured 5 mins before as well as 5, 10, 20, 30 and 40 mins after *i.pag.* or *i.c.v.* microinjections. For the mice that underwent restraint stress, *i.pag* or *i.c.v.* microinjections of the antagonists were performed 5 mins before stress, and nociceptive responses were measured immediately, 5, 10, 20, 30 and 40 mins after stress. After the final behavioural evaluation, the animals were microinjected with 0.5 μl of 0.4% trypan blue solution (Sigma-Aldrich, St. Louis, MO, USA) through the guide cannula to verify the injection tract location. Animals were then sacrificed by decapitation, coronal brain sections (300 μm) were prepared on a vibratome (DSK microslicer DTK-1000, Dosaka, Japan). The injection site was identified by the presence of trypan blue stain diffusion in the vlPAG tissue. Only animals with the cannula correctly targeting the ventricle or vlPAG were included in data analysis.

Measurements of substance P in vlPAG and NPS in LH of brain tissue homogenates {#Sec8}
------------------------------------------------------------------------------

The preparation of the mouse vlPAG and LH homogenate is the same as previously reported \[[@CR12]\]. Briefly, immediately after restraint stress, the mouse was sacrificed. Its brain was removed, placed in a pre-cooled adult mouse brain slicer matrix (Roboz Surgical Instrument, Gaithersburg, MD, USA), and sliced into 1 mm-thick coronal sections. vlPAG or LH brain tissues were bilaterally punched out with a 0.5 mm-tip according to a mouse brain atlas \[[@CR44]\]. Each vlPAG sample was collected from one mouse brain, whereas each LH sample was from two mouse brains. After ultrasonication in lysis buffer, the lysates were homogenized and centrifuged (1900 g,14,000 rpm, 15 min) and supernatants collected. The protein concentration in the supernatant was measured by the Bradford method \[[@CR45]\].

The substance P level in the vlPAG homogenate was measured with an EIA kit (Cat. No. 583751, Cayman Chemical. Ann Arbor, MI, USA) with a detection range of 3.9--500 pg/ml. The NPS level in the LH homogenates was measured with an ELISA kit. (Cat. No. CSB-EL016026MO, Cusabio, College Park, MD, USA) with a detection range of 4.69--300 pg/ml.

Chemicals {#Sec9}
---------

NPS and \[tBu-D-Gly^5^\] NPS were synthesised and purified as previously described \[[@CR46]\]. N-(2-methyl-6-benzoxazolyl)-N-1,5-naphthyridin-4-yl-urea (SB-334867, a selective OX~1~R antagonist), 6-methyl-2-(phenylethynyl) pyridine hydrochloride (MPEP, a selective mGlu~5~R antagonist) and orexin-A were purchased from Tocris Bioscience (Bristol, UK). Substance P, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251, a CB~1~R antagonist), and *cis*-2-(Diphenylmethyl)-N-\[(2-iodophenyl)methyl\]-1-azabicyclo \[2.2.2\] octan-3-amine oxalate salt (L-703,606, a selective NK~1~R antagonist) were purchased from Sigma-Aldrich. NPS and \[tBu-D-Gly^5^\] NPS were dissolved in 0.9% normal saline. Substance P was dissolved in 0.1 M acetic acid. SB-334867, L-703,606, MPEP and AM251 were dissolved in dimethyl sulfoxide (DMSO). All drugs were prepared at the working concentration for the intended *i.pag.* or *i.c.v.* injection doses.

Statistical analysis {#Sec10}
--------------------

Data are expressed as the mean ± S.E.M. and the "n" indicates the number of mice tested in each group. In the hotplate test, two-way ANOVA with post hoc Bonferroni test was used to analyse time courses of antinociceptive effects among different groups. The antinociceptive effect was also assessed by the area under the curve (AUC) of the time courses of quantification of the line graph from baseline to the last time-point of the experiment. Each AUC bar graph was calculated by one-way ANOVA followed by Tukey's multiple comparison test. Student's T-test was employed to analyse the results obtained in EIA and ELISA tests. Differences were considered significant if *p* \< 0.05.

Results {#Sec11}
=======

NPS is antinociceptive when given by *i.c.v.* but not *i.pag*. microinjection in mice {#Sec12}
-------------------------------------------------------------------------------------

NPS when given by *i.c.v.* injection at the doses 0.3 and 1.0 nmol, which did not affect the spontaneous locomotor activity of mice (Additional file [2](#MOESM2){ref-type="media"}: Figure S2), significantly prolonged the latency of nociceptive response in the hot-plate test (Fig. [2](#Fig2){ref-type="fig"}a and b) in a time- (F~6,38~ = 5.696, *p* \< 0.001, two-way ANOVA, Fig. [2](#Fig2){ref-type="fig"}a) and treatment-dependent (F~4,23~ = 10.25, *p* \< 0.001, two-way ANOVA, Fig. [2](#Fig2){ref-type="fig"}a) manner. However, when NPS was given by *i.pag.* microinjection, it did not produce significant antinociceptive effect at either 0.3 or 1.0 nmol (Fig. [2](#Fig2){ref-type="fig"}a and b). This suggests that the site of action for NPS-induced supraspinal antinociception is brain region(s) other than the vlPAG. Fig. 2Antinociceptive effects induced by NPS, orexin-A and substance P in the mouse hot-plate test. **a-b**: Antinociceptive effects of NPS (0.3 & 1.0 nmol) by *i.c.v.* or *i.pag.* microinjection. **c-d**: Antinociceptive effects of *i.c.v.* NPS challenged by an NPSR antagonist, \[tBu-D-Gly^5^\] NPS (10 nmol, *i.c.v.*). **e-f:** A comparison of antinociceptive effects of orexin-A (1 nmol, *i.pag.*), substance P (5 nmol, *i.pag.*), and NPS (0.3 nmol, *i.c.v.*). **a, c** and **e**: The time course of the antinociceptive effect expressed as the percentage of the maximal possible effect (MPE) (two-way ANOVA /post hoc Bonferroni test). **b, d** and **f**: The area under the curve (AUC) of the % MPE measured within 40 min in each treatment group (one-way ANOVA /post hoc Tukey test**)**. The number denoted in the parentheses above each bar is the *n* number of mice tested in each group. Data are mean ± S.E.M. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs. the vehicle control group, ^\#\#\#^*p* \< 0.001 vs. NPS 0.3 or 1.0 group

NPS (*i.c.v.*)-induced antinociception was antagonized by *i.c.v.* blockade of NPSRs {#Sec13}
------------------------------------------------------------------------------------

To investigate if the central antinociceptive effect of NPS is mediated via NPSR, we co-administered \[tBu-D-Gly^5^\] NPS (10 nmol, *i.c.v.*), a selective and potent NPSR antagonist \[[@CR47]\], along with NPS (0.3 or 1.0 nmol, *i.c.v.*) to mice before the hot-plate test. \[tBu-D-Gly^5^\] NPS at 10 nmol (*i.c.v.*) did not affect the nociceptive response in naïve mice, but completely blocked the antinociceptive effect of *i.c.v.* NPS at the doses of 0.3 and 1.0 nmol (Fig. [2](#Fig2){ref-type="fig"}c and d) The overall comparison of the time course of the antinociceptive effect showed a significant difference between time and treatment (F~30,222~ = 1.872, *p* = 0.0057, two-way ANOVA, Fig. [2](#Fig2){ref-type="fig"}c). This suggests the central antinociceptive effect of NPS is mediated by NPSRs in the brain.

NPS (0.3 nmol, *i.c.v.*), substance P (5 nmol, *i.pag.*) and orexin-A (1 nmol, *i.pag.*) induced comparable antinociceptive effects in mice {#Sec14}
-------------------------------------------------------------------------------------------------------------------------------------------

To substantiate our hypothesis that a cascade mediated by NPS, orexins and substance P sequentially is involved in SIA, we evaluated equipotent doses of these three neuropeptides in a concurrent behavioural assay. As shown in Fig. [2](#Fig2){ref-type="fig"}e and f, NPS (0.3 nmol, *i.c.v.*) produced a antinociceptive effect in the mouse hot-plate test that was comparable to the effects induced by *i.pag.* microinjection of orexin-A at 1 nmol and *i.pag.* substance P at 5 nmol, respectively, with a significant difference between time and treatment (F~18,120~ = 1.924, *p* = 0.0198, two-way ANOVA, Fig. [2](#Fig2){ref-type="fig"}e).

Substance P (*i.pag*)-induced antinociception was antagonized by *i.pag.* blockade of NK~1~Rs, mGlu~5~Rs or CB~1~Rs {#Sec15}
-------------------------------------------------------------------------------------------------------------------

To ascertain if the NK~1~R-mGlu~5~R-CB~1~R pathway revealed by the electrophysiological study of Drew et al. (2009) \[[@CR36]\] is involved in *i.pag.* substance P-induced antinociceptive effect, we challenged the antinociceptive effect of substance P with selective antagonists of NK~1~Rs (L-703,606), mGlu~5~Rs (MPEP) and CB~1~Rs (AM251), respectively, in a treatment-dependent manner (F~3,18~ = 5.316, *p* = 0.0084, two-way ANOVA, Fig. [3](#Fig3){ref-type="fig"}a; F~3,18~ = 10.97, *p* = 0.0003, two-way ANOVA, Fig. [3](#Fig3){ref-type="fig"}b; F~3,17~ = 5.929, *p* = 0.0059, two-way ANOVA, Fig. [3](#Fig3){ref-type="fig"}c). Indeed, *i.pag.* co-administration of L-703,606 (10 nmol), MPEP (30 nmol) or AM251 (30 nmol) with substance P (5 nmol) significantly antagonized the antinociceptive effect of *i.pag.* substance P (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Substance P (*i.pag.*)-induced antinociception is antagonized by *i.pag.* blockade of NK~1~Rs, mGlu~5~Rs or CB~1~Rs. **a**-**c**: Time courses of antinociceptive effects (expressed as % MPE) induced by substance P (5 nmol, *i.pag.*) in combination with the vehicle or the antagonist of NK~1~Rs (L-703,606, 10 nmol, *i.pag.*, **a**, mGlu~5~Rs (MPEP, 30 nmol, *i.pag.*, **b**, and CB~1~Rs (AM251, 30 nmol, *i.pag.*, **c** in the mouse hot-plate test. (two-way ANOVA /post hoc Bonferroni test**). d:** The AUC of the antinociceptive effect in each treatment group **(**one-way ANOVA /post hoc Tukey test**)**. The antagonist was *i.pag.* co-administered with *i.pag.* substance P. The data presentation and statistics are the same as in Fig. [2](#Fig2){ref-type="fig"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs. the vehicle control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. the Substance P group

Orexin-A (*i.pag.*)-induced antinociception was antagonized by *i.pag.* blockade of NK~1~Rs and mGlu~5~Rs {#Sec16}
---------------------------------------------------------------------------------------------------------

Our previous findings that *i.pag.* orexin-A induced antinociception through an OX~1~R-initiated eCB signalling \[[@CR11]\], where the downstream mechanism was highly similar to *i.pag.* substance P induced antinociception as shown in the subsection above. In order to ascertain the interaction between orexin-A and substance P in the vlPAG, we challenged orexin-A-induced antinociception with *i.pag.* NK~1~R and mGlu~5~R antagonists, respectively. Co-administration of L-703,606 (10 nmol, *i.pag.*) or MPEP (30 nmol, *i.pag.*) significantly antagonized *i.pag*. orexin-A (1 nmol)-induced antinociception (Fig. [4](#Fig4){ref-type="fig"}). The overall comparison of time courses of the antinociceptive effect showed a significant difference between time and treatment (F~18,108~ = 3.841, *p* \< 0.001, two-way ANOVA, Fig. [4](#Fig4){ref-type="fig"}a; F~18,108~ = 4.597, *p* \< 0.001, two-way ANOVA, Fig. [4](#Fig4){ref-type="fig"}b). These results in combination with our previous findings suggest that orexin-A-induced antinociception is mediated by OX~1~Rs, NK~1~Rs, mGlu~5~Rs and CB~1~Rs sequentially in the vlPAG. Fig. 4Orexin-A (*i.pag.*)-induced antinociception is antagonized by *i.pag.* blockade of NK~1~Rs or mGlu~5~Rs. **a**-**b**: Time courses of antinociceptive effects (expressed as % MPE) induced by orexin-A (1.0 nmol, *i.pag.*) in combination with the vehicle or the antagonist of NK~1~Rs (L-703,606, 10 nmol, *i.pag.,* **a** or mGlu~5~Rs (MPEP, 30 nmol, *i.pag.*, **b** in the mouse hot-plate test. (two-way ANOVA /post hoc Bonferroni test**). c:** The AUC of the antinociceptive effect in each treatment group **(**one-way ANOVA /post hoc Tukey test**)**. The antagonist was *i.pag.* co-administered with *i.pag.* orexin-A. The data presentation and statistics are the same as in Fig. [2](#Fig2){ref-type="fig"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs. the vehicle control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. the orexin-A group

NPS (*i.c.v.*)-induced antinociception was antagonized by *i.pag.* blockade of OX~1~Rs, NK~1~Rs, mGlu5Rs or CB~1~Rs {#Sec17}
-------------------------------------------------------------------------------------------------------------------

Next, we investigated whether the now established OX~1~R-NK~1~R-mGlu~5~R-CB~1~R cascade in the vlPAG is involved in the supraspinal antinociceptive effect of NPS. Co-administration of the respective antagonists of OX~1~Rs (SB-334867, 15 nmol, *i.pag.*), NK~1~Rs (L-703,606, 10 nmol, *i.pag.*), mGlu~5~Rs (MPEP, 30 nmol, *i.pag.*) or CB~1~Rs (AM251, 30 nmol, *i.pag.*), significantly supressed the antinociceptive effect of *i.c.v.* NPS (0.3 nmol) (Fig. [5](#Fig5){ref-type="fig"}), in a time- (F~6,114~ = 3.252, *p* = 0.0055, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}a; F~6,114~ = 2.936, *p* = 0.0106, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}b; F~6,114~ = 2.603, *p* = 0.211, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}c; F~6,114~ = 2.2, *p* = 0.0479, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}d) and treatment- (F~3,19~ = 36.96, *p* \< 0.001, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}a; F~3,19~ = 28.58, *p* \< 0.001, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}b; F~3,19~ = 67.33, *p* \< 0.001, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}c; F~3,19~ = 23.44, *p* \< 0.001, two-way ANOVA, Fig. [5](#Fig5){ref-type="fig"}d) dependent manner. Thus, *i.c.v.* NPS-induced analgesia is mediated by the OX~1~Rs, NK~1~Rs, mGlu~5~Rs and CB~1~Rs in the vlPAG. Fig. 5NPS (*i.c.v.*)-induced antinociception is antagonized by *i.pag.* blockade of OX~1~Rs, NK~1~Rs, mGlu~5~Rs or CB~1~Rs. **a**-**d**: Time courses of antinociceptive effects (expressed as % MPE) induced by NPS (0.3 nmol, *i.c.v.*) in combination with the vehicle or the antagonists of OX~1~Rs (SB-334867, 15 nmol, *i.pag.*), NK~1~Rs (L-703,606, 10 nmol, *i.pag.*), mGlu~5~Rs (MPEP, 30 nmol, *i.pag.*) or CB~1~Rs (AM251, 30 nmol, *i.pag.*) in the mouse hot-plate test. (two-way ANOVA /post hoc Bonferroni test**). e:** The AUC of the antinociceptive effect in each treatment group **(**one-way ANOVA /post hoc Tukey test**)**. The antagonist was *i.pag.* Administered immediately before *i.c.v.* injection of NPS. The data presentation and statistics are the same as in Fig. [2](#Fig2){ref-type="fig"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs. the vehicle control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. the NPS group

Restraint stress-induced analgesia was prevented by *i.c.v.* blockade of NPSR or *i.pag.* blockade of OX~1~Rs, NK~1~Rs or mGlu~5~Rs {#Sec18}
-----------------------------------------------------------------------------------------------------------------------------------

We have previously demonstrated that the vlPAG OX~1~R-CB~1~R pathway is involved in the SIA induced by an acute restraint stress in mice \[[@CR12]\]. We subsequently examined whether the now established NPSR-OX~1~R-NK~1~R-mGlu5R-CB~1~R cascade is involved in the SIA induced by the same restraint stress protocol. Mice receiving an acute restraint stress for 30 min exhibited significant reduced paw withdrawal response in the hot-plate test. This SIA diminished within 20 min (Fig. [6](#Fig6){ref-type="fig"}a) \[[@CR12]\] and was significantly prevented in mice *i.c.v.* pre-treated with an NPSR antagonist (\[tBu-D-Gly^5^\] NPS, 10 nmol) (Fig. [6](#Fig6){ref-type="fig"}a and d) or with *i.pag.* Pretreated with NK~1~R (L-703,606, 10 nmol) (Fig. [6](#Fig6){ref-type="fig"}b and d) and mGlu~5~R (MPEP, 30 nmol) antagonists (Fig. [6](#Fig6){ref-type="fig"}c and d), respectively. The overall comparison of the time course of the antinociceptive effect showed a significant difference between time and treatment (F~18,114~ = 4.317, *p* \< 0.001, two-way ANOVA, Fig. [6](#Fig6){ref-type="fig"}a; F~18,108~ = 3.780, *p* \< 0.001, two-way ANOVA, Fig. [6](#Fig6){ref-type="fig"}b; F~18,108~ = 3.501, *p* \< 0.001, two-way ANOVA, Fig. [6](#Fig6){ref-type="fig"}c). Take together with our previous findings that SB-334867 (15 nmol, *i.pag.*) and AM251 (30 nmol, *i.pag.*) prevented SIA \[[@CR12]\], it is suggested that SIA is mediated via the NPSR-evoked OX~1~R-NK~1~R-mGlu~5~R-CB~1~R cascade in the vlPAG. Fig. 6Restraint stress-induced antinociception (SIA) is prevented by *i.c.v.* blockade of NPSR or by *i.pag.* blockade of NK~1~Rs or mGlu5Rs. **a**-**c**: Time courses of antinociceptive effects (expressed as % MPE) induced by a 30 min-restraint stress (horizontal bars) in mice pre-treated with vehicle or the antagonist of NPSRs (\[tBu-D-Gly^5^\] NPS, 10 nmol, *i.c.v.*), NK~1~Rs (L-703,606, 10 nmol, *i.pag.*) or mGlu~5~Rs (MPEP, 30 nmol, *i.pag.*) in the hot-plate test. (two-way ANOVA /post hoc Bonferroni test). **d:** The AUC of the antinociceptive effect in each treatment group **(**one-way ANOVA /post hoc Tukey test**).** The antagonist was *i.c.v.* or *i.pag.* administered immediately before restraint stress. The data presentation and statistics are the same as in Fig. [2](#Fig2){ref-type="fig"}. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs. the vehicle control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 vs. the Stress group

All the tested antagonists at the administered doses that attenuated SIA had no effect on the number of crossing and rearing, including the NPSR antagonist (\[tBu-D-Gly^5^\] NPS, 10 nmol, *i.c.v.*) (Additional file [3](#MOESM3){ref-type="media"}: Figure S3a and b), the NK~1~R antagonist (L-703,606, 10 nmol, *i.pag.*) (Additional file [3](#MOESM3){ref-type="media"}: Figure S3, C and D) and the mGlu~5~R antagonist (MPEP, 30 nmol, *i.pag.*) (Additional file [3](#MOESM3){ref-type="media"}: Figure S3**,** E and F), similar to the OX~1~R antagonist (SB-334867, 15 nmol, *i.pag.*) and the CB~1~R antagonist (AM251, 30 nmol, *i.pag.*) which we have reported previously \[[@CR12]\]. This supports that these antagonists attenuate SIA by blocking their respective endogenous ligands.

Restraint stress elevated NPS level in LH and substance P level in vlPAG {#Sec19}
------------------------------------------------------------------------

Measurement of the neuropeptide content in the brain homogenate revealed that restrain stress significantly elevated the NPS level in the LH (df = 12, t = 2.987, *p* \< 0.05, Student's t-test, Fig. [7](#Fig7){ref-type="fig"}a) and the substance P level in the vlPAG (df = 9, t = 2.72, *p* \< 0.05, Student's t-test, Fig. [7](#Fig7){ref-type="fig"}b). Similar elevations in orexin-A levels were observed in the vlPAG of restrained mice as we previously reported \[[@CR12]\]. Fig. 7Restraint stress increases the NPS level in the LH (**a**) and the substance P level in the vlPAG. (**b**) Brain tissues containing the LH or vlPAG were punched and homogenized from restrained mice immediately after a 30 min-restraint stress (stress group) or from unrestrained control mice (non-stress group). NPS levels in LH homogenates were measured by an ELISA kit (Cusabio, College Park, MD, USA), whereas substance P level in vlPAG homogenates were measured by an EIA kit (Caymon Chemical. Ann Arbor, MI, USA). \**p* \< 0.05, \*\**p* \< 0.01 vs. the Non-stress control group (Student's t-test)

Discussion {#Sec20}
==========

In this study, we found that the antinociceptive effect of *i.c.v.* NPS was blocked by *i.c.v.* injection of an NPSR antagonist and *i.pag.* injection of antagonists for OX~1~Rs, NK~1~Rs, mGlu~5~Rs and CB~1~Rs, respectively. These results suggest that orexins, substance P, glutamate and eCBs in the vlPAG are involved in supraspinal NPS-induced antinociception. In addition, blockade of either NPSRs, OX~1~Rs, NK~1~Rs, mGlu~5~Rs or CB~1~Rs suppressed the antinociception induced by a 30 min-restraint stress that increased the NPS level in the LH as well as the substance P level in the vlPAG. This suggests that NPS plays a role in SIA by activating the OX~1~R-NK~1~R-mGlu~5~R-CB~1~R-mediated sequential cascade that leads to antinociception through a disinhibition mechanism (i.e. inhibition of GABA release) mediated by GqPCR-PLC-DAGL-2-AG-CB~1~R signalling in the vlPAG \[[@CR11], [@CR12]\] (Fig. [8](#Fig8){ref-type="fig"}). Our results also suggest that restraint stress suppresses pain sensitivity in vivo by engaging the NPS-orexin-A-substance P-glutamate signalosome to initiate the eCB-mediated retrograde disinhibition mechanism in the vlPAG. Integrating with the existing literature, the findings from the present study may fill in the gaps, denoted as \[★\], among the signalling pathways of SIA as demonstrated by several research groups, as illustrated in Fig. [1](#Fig1){ref-type="fig"}. Fig. 8A proposed schema illustrating how NPS, orexins, substance P, mGlu~5~R and endocannabinoid (2-AG) may be involved in SIA. Before stress, the projection neurons in the vlPAG is under GABAergic inhibitory control. During stress, hypothalamic orexin neurons (OX) are activated by NPS, which is released possibly from the NPS neurosn in peri-LC and/or the KF-PBN in mice \[[@CR24]\], releasing orexins that activate the OX~1~Rs on neurokinin (SubP) neurons and release substance P in the vlPAG. Then, substance P activates the NK~1~R-containing glutamate (Glu) neurons, yielding massive glutamate that in turn activates perisynaptic mGlu~5~Rs to initiate the GqPCR signalling and generate 2-AG. This endocannabinoid then retrogradely activates presynaptic CB~1~Rs to inhibit GABA release in the vlPAG, ultimately leading to analgesia. The points of pharmacological intervention performed in this study are marked with blunt arrows, labelled with the respective antagonists. The images of neurons are adapted from Illustration Toolkit Neuroscience by Motifolio. PN: projection neuron. GABA~A~R: GABA~A~ receptor

Substance P exerted antinociceptive effect via NK~1~Rs, mGlu~5~Rs and CB~1~Rs in the vlPAG {#Sec21}
------------------------------------------------------------------------------------------

Drew et al. \[[@CR36]\], using an electrophysiological approach, has shown that, in the vlPAG, substance P can facilitate the release of glutamate that subsequently activates postsynaptic mGlu~5~Rs located at perisynaptic sites, leading to the synthesis of 2-AG that retrogradely inhibits presynaptic GABA release via CB~1~Rs. Gregg et al. \[[@CR40]\], using a behavioural approach, also demonstrated that activating mGlu~5~Rs in the PAG can induce an antinociceptive effect mediated by 2-AG and CB~1~Rs. Here, we further demonstrated that this substance P-initiated and mGlu~5~R-mediated eCB retrograde signalling contributes to the antinociceptive effect of substance P in the vlPAG since *i.pag.* substance P-induced antinociception was antagonized by *i.pag.* blockade of NK~1~Rs, mGlu~5~Rs or CB~1~Rs. The present study also supports that substance P is antinociceptive at the supraspinal level and the vlPAG is one of the sites of action.

The substance P-NK~1~R-glutamate-mGlu~5~R cascade acts downstream of orexin-induced antinociception in the vlPAG {#Sec22}
----------------------------------------------------------------------------------------------------------------

The finding that the NK~1~R antagonist attenuated orexin-induced antinociception in the vlPAG (Fig. [4](#Fig4){ref-type="fig"}) suggests that substance P acts downstream of orexin-induced antinociception. This finding is in agreement with a recent study that reported that the level of substance P in the vlPAG was increased following *i.pag.* orexin-A administration in rats \[[@CR48]\]. Previously, we have shown that orexin via OX1Rs induces analgesia through a GqPCR-PLC-DAGL-2-AG-CB~1~R retrograde disinhibition mechanism in the vlPAG \[[@CR11]\]. Given that mGlu~5~R, a GPCR, is also coupled to Gq proteins and mediates the antinociceptive effect via the same 2-AG-dependent disinhibition mechanism in the PAG \[[@CR40]\] as the OX~1~R \[[@CR11]\], it is reasonable to suggest that the mGlu~5~R is a downstream target after OX~1~R-NK~1~R activation. That is, orexin may induce analgesia via a cascade mediated by the OX~1~R-substance P-NK~1~R-glutamate-mGlu~5~R-PLC-DAGL-2-AG-CB~1~R signalling sequentially in the PAG (Fig. [8](#Fig8){ref-type="fig"}).

This sequential cascade may be able to explain the previous finding that *i.pag.* blockade of NK~1~Rs attenuated LH stimulation-induced antinociception \[[@CR49]\]. It is likely that orexin is the mediator released from the LH to induce antinociception indirectly via the NK~1~R in the PAG. Additionally, involvement of substance P in the antinociceptive effect of orexin may also explain our previous electrophysiological finding that, in certain recorded vlPAG neurons, orexin-A did not induce postsynaptic depolarization but attenuated GABA release via presynaptic CB~1~Rs \[[@CR11]\]. In addition to the 2-AG spill-over hypothesis, orexin-A may activate neurokinin neurons to release substance P that indirectly inhibits GABA release via mGlu~5~R-eCB signalling in those neurons that were not depolarized by orexin-A.

The PAG is not the site of action for NPS-induced supraspinal antinociception {#Sec23}
-----------------------------------------------------------------------------

In agreement with previous studies that *i.c.v.* NPS was antinociceptive in swiss mice \[[@CR19]--[@CR21]\], we also found *i.c.v.* NPS reduced the hot-plate nociceptive response in C57BL/6JNarl mice. Peng et al. \[[@CR20]\] suggested that the PAG is likely the site of action of NPS since *i.c.v.* NPS increased the c-Fos expression in the PAG where the NPSR mRNA is abundant \[[@CR23]\]. However, our findings that direct *i.pag.* microinjection of NPS failed to induce antinociception and that *i.c.v.*, but not *i.pag.*, blockade of NPSRs antagonized *i.c.v.* NPS-induced antinociception indicate that *i.c.v.* NPS may act in brain regions other than the PAG to exert its antinociceptive effect.

NPS-induced antinociception is mediated via OX~1~R-NK~1~R-mGlu~5~R-CB~1~R sequentially in the vlPAG {#Sec24}
---------------------------------------------------------------------------------------------------

The findings that *i.pag.* blockade of OX~1~Rs, NK~1~Rs, mGlu~5~Rs and CB~1~Rs prevented *i.c.v.* NPS-induced antinociception suggest the involvement of the OX~1~R-NK~1~R-mGlu~5~R-CB~1~R signalling in the vlPAG in the supraspinal antinociceptive action of NPS. The site of action is likely in the hypothalamic areas where orexin neurons are located, especially the LH that is involved in pain regulation. Ideally, it would be more precise to study the action of NPS and its antagonist on orexin neurons in the LH via intra-LH microinjection. However, due to the difficulty of performing both intra-LH and *i.pag*. cannulations in mice, *i.c.v.* and *i.pag*. microinjections were employed (Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}). Nevertheless, several studies have suggested an interaction between NPS and orexin systems. Anatomical and functional studies suggest that NPS can activate orexin neurons and may modulate biological functions indirectly via released orexins. First, the hypothalamic regions where orexin neurons are located, including the LH, PFA, and DMH, are enriched with NPSRs \[[@CR23]\]. Second, after *i.c.v.* injection of NPS in rats, fos-immunoreactive cells in the hypothalamus, especially in the LH, were orexin-A-positive \[[@CR27], [@CR28]\]. Third, NPS has been reported to be an upstream activator of the orexin system in feeding \[[@CR27]\] and addiction \[[@CR28]\] behaviours acting in the hypothalamus. Therefore, it is likely that NPS activates the orexin neurons at the LH, releasing orexins in the vlPAG to induce antinociception.

SIA is mediated by endogenous NPS-initiated hypothalamic orexins via the OX~1~R-NK~1~R-mGlu~5~R-CB~1~R-mediated sequential cascade in the vlPAG {#Sec25}
-----------------------------------------------------------------------------------------------------------------------------------------------

Previously, we have demonstrated that SIA is mediated by orexins released from the LH, an important region for SIA \[[@CR13]\], via an OX~1~R-initiated 2-AG-dependent disinhibition mechanism in the vlPAG \[[@CR12]\]. Here, we extend the findings in this study to suggest that NPS activates hypothalamic orexin neurons and add substance P as downstream of vlPAG OX~1~R activation in this SIA mechanism. That is, during stress, hypothalamic orexin neurons are activated by NPS, which is released possibly from the peri-LC and/or the KF-PBN in mice \[[@CR24]\], releasing orexins that activate the OX~1~Rs on neurokinin neurons in the vlPAG. Then, substance P is released and activates the NK~1~R-containing glutamate neurons, yielding massive glutamate release that in turn activates perisynaptic mGlu~5~Rs to initiate GqPCR signalling and generation of 2-AG. This eCB then retrogradely activates presynaptic CB~1~Rs to inhibit GABA release in the vlPAG, ultimately leading to analgesia (Figs. [1](#Fig1){ref-type="fig"} and [8](#Fig8){ref-type="fig"}). This conclusion is based on the following findings, which may fill the gaps \[★\] in the schema depicted in Fig. [1](#Fig1){ref-type="fig"}, that (1) stress increased NPS levels in the LH (Fig. [7](#Fig7){ref-type="fig"}a) and SIA was reduced by blocking NPSRs (Fig. [6](#Fig6){ref-type="fig"}a); (2) stress increased orexin levels in the vlPAG and SIA was reduced by blocking OX~1~Rs in the vlPAG \[[@CR12]\]; (3) stress increased substance P levels (Fig. [7](#Fig7){ref-type="fig"}b) and SIA was reduced by blocking NK~1~Rs in the vlPAG (Fig. [6](#Fig6){ref-type="fig"}b); (4) SIA was reduced by blocking either mGlu~5~Rs (Fig. [6](#Fig6){ref-type="fig"}c), CB~1~Rs or DAGL in the vlPAG \[[@CR12]\]. The antagonist/inhibitor of NPSRs (BuG-NPS, Fig. [6](#Fig6){ref-type="fig"}a), OX~1~Rs (SB-334867) \[[@CR12]\], NK~1~Rs (L-703,606, Fig. [6](#Fig6){ref-type="fig"}b), mGlu~5~Rs (MPEP, Fig. [6](#Fig6){ref-type="fig"}c), CB~1~Rs (AM251) or DAGL (tetrahydrolipstatin) \[[@CR12]\] employed at the dose blocking SIA, per se, did not affect nociceptive threshold in unrestrained normal mice, suggesting no non-specific effects of these antagonists employed at the concentrations used in this study.

Since 1990s, substance P has been reported to play a role in SIA while the site(s) of action remain unidentified. Rosen et al. \[[@CR38]\] reported that substance P was released from the PAG of animals in response to a behavioural stress, suggesting that endogenous substance P contributes to SIA originated from the PAG-mediated descending pain inhibition. The finding that the antinociceptive effect induced by stimulating the LH was abolished by *i.pag.* L-703,606 \[[@CR39]\], suggesting that stimulating the LH can release substance P to induce antinociception via the NK~1~Rs in the PAG. Here, we provided direct evidence supporting that SIA is mediated by elevated substance P in the PAG.

Several lines of evidence have indicated the involvement of NPS in stress-induced responses. NPSRs are enriched in the amygdala and hypothalamus \[[@CR22]\], stress-related brain regions. The number of c-fos-containing NPS neurons in the peri-LC and KF-PBN was increased after a short-term forced swim stress or restraint stress \[[@CR24]\]. The current finding that the acute restraint stress that induces analgesia can increase the NPS level in the LH directly supports that NPS is released during stress and contributes to SIA.

Several reports have indicated a cross-modulatory relationship between NPS and the corticotrophin releasing factor (CRF) system in stress-related responses. Paneda et al. \[[@CR50]\] reported that CRF~1~ receptor may mediate NPS-induced cocaine reinstatement in mice. Conversely, Jungling et al. \[[@CR4]\]. demonstrated that CRF can modulate NPS neurons in the LC of mice following acute stress. It remains to be elucidated if interactions between the CRF system and the NPSR-OX~1~R-NK~1~R-mGlu~5~R-CB~1~R-mediated sequential cascade in SIA occur.

Limitations of the current study {#Sec26}
--------------------------------

In the current study, we found that NPS (*i.c.v.*) at 0.3 and 1 nmol in C57BL/6 did not induce significant hyperlocomotion (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). This is different with previous studies, where *i.c.v.* NPS at doses of 0.1 and 1.0 nmol induced hyperlocomotion in C57BL/6 \[[@CR50]\] and Swiss mice \[[@CR4]\]. However, Rizzi et al. \[[@CR51]\], Castro et al. \[[@CR52]\] and Boeck et al. \[[@CR53]\] consistently demonstrated that *i.c.v.* NPS, only at the dose of 0.1 nmol, but not 0.01 and 1.0 nmol, exhibited significant hyperlocomotion in CF-1 mice. Furthemore, Holanda et al. \[[@CR21]\] reported that *i.c.v.* NPS at 0.1 nmol did not increase locomotor activity in CF-1 mice. The discrepancy among studies is unclear. It may be that the *i.c.v.* NPS doses employed under the conditions (mouse strain and the motor activity assessment) in the present study fall outside the optimal dose for inducing hyperlocomotion.

Conclusions {#Sec27}
===========

During stress, NPS is released to activate hypothalamic orexin neurons, releasing orexins that activate OX~1~Rs on neurokinin neurons in the vlPAG, releasing substance P that activates NK~1~Rs on glutamate neurons, yielding massive glutamate that in turn activates perisynaptic mGlu~5~Rs to initiate the G~q~PCR signalling and then generate 2-AG, which then. Retrogradely activates presynaptic CB~1~Rs to inhibit GABA release in the vlPAG, ultimately leading to analgesia (Fig. [8](#Fig8){ref-type="fig"}).

Supplementary information
=========================

 {#Sec28}

**Additional file 1:** **Figure S1.** The representative diagram of *i.pag.* (A) and *i.c.v.* (B) microinjections in mice. The diagrams were adapted from mouse brain atlas \[[@CR44]\]. The black dots (**A**) and white dots (**B**) represent the microinjection sites. **Additional file 2:** **Figure S2.** Effects of NPS on locomotor activity. Locomotor activity in the open field test was measured before and 10 min after *i.c.v.* administration of 0.3 nmol (**A-B**) or 1 nmol (**C-D**) of NPS. Locomotor activity was assessed by the number of crossing (**A & C**) and rearing (**B & D**) in the open field test for 5 min. Data are expressed as the mean ± S.E.M. (Unpaired t-test) **Additional file 3:** **Figure S3.** Effects of \[tBu-D-Gly^5^\] NPS, L-703,606 or MPEP on locomotor activity. Locomotor activity in the open field test was measured before and 10 min after administration of \[tBu-D-Gly^5^\] NPS (10 nmol, *i.c.v.*) (**A-B**), L-703,606 (10 nmol, *i.pag.*) (**C-D**), or MPEP (30 nmol, *i.pag.*) (**E-F**). Locomotor activity was assessed by the number of crossing (**A, C & E**) and rearing (**B, D & F**) in the open field test for 5 min. Data are expressed as the mean ± S.E.M. (Unpaired t-test)

2-AG

:   2-arachidonoylglycerol

AM251

:   1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide,CB~1~R, CB~1~ receptor

CRF

:   Corticotrophin releasing factor

DAGL

:   Diacylglycerol lipase

DMH

:   Dorsomedial hypothalamus

eCB

:   endocannabinoid

EIA

:   Enzyme immunoassay

ELISA

:   Enzyme-linked immunosorbent assay

GqPCR

:   Gq-protein coupled receptor

HPA

:   Hypothalamus-pituitary axis

*i.c.v.*

:   intra-cerebroventricular

*i.pag*

:   intra-ventrolateral periaqueductal gray

L-703,606

:   cis-2-(Diphenylmethyl)-N-\[(2-iodophenyl)methyl\]-1-azabicyclo \[2.2.2\] octan-3-amine oxalate salt

LC

:   Locus coeruleus

LH

:   Lateral hypothalamus

mGlu~5~R

:   mGlu~5~ receptor

MPE

:   Maximal possible effect

MPEP

:   2-methyl-6-(phenylethynyl) pyridine hydrochloride

NK~1~R

:   NK~1~ receptor

NPS

:   Neuropeptide S

NPSR

:   Neuropeptide S receptor

OX~1~R

:   OX~1~ receptor

OX~2~R

:   OX~2~ receptor

PBN

:   Parabrachial nucleus

PFA

:   Perifornical area

PLC

:   Phospholipase C

PVN

:   Paraventricular nucleus

SB-334867

:   N-(2-Methyl-6-benzoxazolyl)-N′-1,5-naphthyridin-4-yl urea

SIA

:   Stress-induced analgesia

vlPAG

:   ventrolateral periaqueductal gray

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ming Tatt Lee, Yu-Ting Chiu and Yu-Chun Chiu contributed equally to this work.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s12929-019-0590-1.

We appreciate the contribution from Prof. Ken Mackie (Indiana University Bloomington, USA) for providing critical comments and suggestions in improving this manuscript.

MTL contributed to data interpretation, data analysis, results discussion and paper writing; YTC and YCC conducted experiments, analyzed data and paper writing; CCH and HJL conducted the experiments; RG and GC synthesized and provided compounds as well as contributed to results discussion; LCC designed experiments, analyzed data and wrote the paper. All authors read and approved the final manuscript.

This study was supported by grants from the Ministry of Science and Technology, Taiwan (MOST104--2314-B-002-053-MY3, MOST106--2321-B-002-019, MOST106--2811-B-002-124, MOST107--2321-B-002-010, MOST107--2811-B-002-008, MOST 108--2321-B-002-005 and MOST 108--2320-B-002-029-MY3), National Health Research Institutes, Taiwan (NHRI-EX102-10251NI, NHRI-EX107-10733NI) and Ministry of Education, Taiwan (107 M4022--3).

All data generated or analyzed during this study are included in this published article and its supplementary information files.

All animal experiments were approved by the Institutional Animal Care and Use Committee of College of Medicine, National Taiwan University following ARRIVE guidelines.

Not applicable.

The authors declare that they have no competing interests.
